De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR–): survival outcomes from a multicentre, open-label, randomised, phase 2 trial
Several de-escalation neoadjuvant strategies have been investigated to reduce the use of chemotherapy in HER2-positive early breast cancer using pathological complete response as a surrogate endpoint; there are few survival data from these trials. Here, we report 5-year survival data in the WSG-ADAP...
Saved in:
| Published in | The lancet oncology Vol. 23; no. 5; pp. 625 - 635 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Elsevier Ltd
01.05.2022
Elsevier Limited |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1470-2045 1474-5488 1474-5488 |
| DOI | 10.1016/S1470-2045(22)00159-0 |
Cover
| Abstract | Several de-escalation neoadjuvant strategies have been investigated to reduce the use of chemotherapy in HER2-positive early breast cancer using pathological complete response as a surrogate endpoint; there are few survival data from these trials. Here, we report 5-year survival data in the WSG-ADAPT-HER2+/HR– trial and address the effect of pathological complete response, early therapy response, and molecular subtype.
WSG-ASAPT-HER2+/HR–, a part of the ADAPT umbrella trial performed in patients with different subtypes of early breast cancer, was an investigator-initiated, multicentre, open-label, randomised, phase 2 trial done at 40 Breast Cancer Centres in Germany. Eligible patients were aged 18 years or older with histologically confirmed, unilateral, primary invasive, non-inflammatory early breast cancer, hormone receptor-negative and HER2-positive status, and an Eastern Cooperative Oncology Group performance status of 0 or 1 or a Karnofsky performance status of at least 80%. Patients were randomly assigned (5:2, block size 21, stratified by centre and clinical nodal status) to 12 weeks of either trastuzumab (8 mg/kg loading dose, then 6 mg/kg every 3 weeks) plus pertuzumab (840 mg loading dose, then 420 mg every 3 weeks) or trastuzumab plus pertuzumab plus paclitaxel (80 mg/m2 weekly); all drugs were administered intravenously. The primary objective of the trial was to compare the number of patients with a pathological complete response at surgery (ie, no invasive tumour cells in breast and lymph nodes [ypT0/is ypN0], the primary endpoint) in early responders (ie, low cellularity or Ki67 decrease ≥30% after 3 weeks) in the trastuzumab plus pertuzumab group versus all patients (irrespective of an early response) in the trastuzumab plus pertuzumab plus paclitaxel group. Non-inferiority was defined as a pathological complete response no worse than 23% lower in the early-responder proportion of patients in the trastuzumab plus pertuzumab group than in the entire trastuzumab plus pertuzumab plus paclitaxel group. The primary endpoint has been reported previously. Additionally, the primary objective of the ADAPT umbrella trial was the evaluation of the effect of pathological complete response on invasive disease-free survival. At investigator's discretion, further chemotherapy could be omitted in patients with a pathological complete response. Secondary survival endpoints were 5-year invasive disease-free survival, relapse-free survival, locoregional relapse-free survival, distant disease-free survival, and overall survival. The effect of pathological complete response on survival was estimated by Cox regression analysis. All analyses are reported in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT01817452, and is closed to recruitment.
Between March 3, 2014, and Oct 6, 2015, 134 patients were recruited and randomly assigned to treatment, 92 to trastuzumab plus pertuzumab and 42 to trastuzumab plus pertuzumab plus paclitaxel. Median follow-up in survivors was 59·9 months (IQR 53·4–61·4). There were no significant differences between the treatment groups in invasive disease-free survival, relapse-free survival, locoregional relapse-free survival, distant disease-free survival, and overall survival. In the trastuzumab plus pertuzumab plus paclitaxel group and in the trastuzumab plus pertuzumab group, the proportions of patients achieving 5-year survival respectively were 98% (95% CI 84–100) and 87% (78–93) for invasive disease-free survival (hazard ratio [HR] 0·32, 95% CI 0·07–1·49; p=0·15); 98% (95% CI 84–100) and 89% (79–94) for relapse-free survival (HR 0·41, 95% CI 0·09–1·91; p=0·25); 100% (95% CI not estimable) and 95% (88–98) for locoregional relapse-free survival (HR 0·41, 95% CI 0·05–3·75; p=0·43); 98% (95% CI 84–100) and 92% (83–96) for distant disease-free survival (HR 0·35, 95% CI 0·04–3·12; p=0·36), and 98% (95% CI 84–100) and 94% (86–97) for overall survival (HR 0·41, 95% CI 0·05–3·63; p=0·43). Pathological complete response was associated with improved invasive disease-free survival (HR 0·14, 95% CI 0·03–0·64; p=0·011). Two invasive disease-free survival events occurred after a pathological complete response (one in each treatment group).
The WSG-ADAPT-HER2+/HR– trial showed good survival rates in patients with a pathological complete response after de-escalated 12-week trastuzumab plus pertuzumab with or without weekly paclitaxel. Omission of further chemotherapy did not affect invasive disease-free survival in patients with a pathological complete response. 12 weeks of weekly paclitaxel plus dual HER2 blockade could be an efficacious de-escalated neoadjuvant regimen in patients with hormone receptor-negative, HER2-positive early breast cancer with high pathological complete response rates and good 5-year outcomes. Further trials of this approach are ongoing.
Roche, Bayer.
For the German translation of the abstract see Supplementary Materials section. |
|---|---|
| AbstractList | Several de-escalation neoadjuvant strategies have been investigated to reduce the use of chemotherapy in HER2-positive early breast cancer using pathological complete response as a surrogate endpoint; there are few survival data from these trials. Here, we report 5-year survival data in the WSG-ADAPT-HER2+/HR– trial and address the effect of pathological complete response, early therapy response, and molecular subtype.
WSG-ASAPT-HER2+/HR–, a part of the ADAPT umbrella trial performed in patients with different subtypes of early breast cancer, was an investigator-initiated, multicentre, open-label, randomised, phase 2 trial done at 40 Breast Cancer Centres in Germany. Eligible patients were aged 18 years or older with histologically confirmed, unilateral, primary invasive, non-inflammatory early breast cancer, hormone receptor-negative and HER2-positive status, and an Eastern Cooperative Oncology Group performance status of 0 or 1 or a Karnofsky performance status of at least 80%. Patients were randomly assigned (5:2, block size 21, stratified by centre and clinical nodal status) to 12 weeks of either trastuzumab (8 mg/kg loading dose, then 6 mg/kg every 3 weeks) plus pertuzumab (840 mg loading dose, then 420 mg every 3 weeks) or trastuzumab plus pertuzumab plus paclitaxel (80 mg/m2 weekly); all drugs were administered intravenously. The primary objective of the trial was to compare the number of patients with a pathological complete response at surgery (ie, no invasive tumour cells in breast and lymph nodes [ypT0/is ypN0], the primary endpoint) in early responders (ie, low cellularity or Ki67 decrease ≥30% after 3 weeks) in the trastuzumab plus pertuzumab group versus all patients (irrespective of an early response) in the trastuzumab plus pertuzumab plus paclitaxel group. Non-inferiority was defined as a pathological complete response no worse than 23% lower in the early-responder proportion of patients in the trastuzumab plus pertuzumab group than in the entire trastuzumab plus pertuzumab plus paclitaxel group. The primary endpoint has been reported previously. Additionally, the primary objective of the ADAPT umbrella trial was the evaluation of the effect of pathological complete response on invasive disease-free survival. At investigator's discretion, further chemotherapy could be omitted in patients with a pathological complete response. Secondary survival endpoints were 5-year invasive disease-free survival, relapse-free survival, locoregional relapse-free survival, distant disease-free survival, and overall survival. The effect of pathological complete response on survival was estimated by Cox regression analysis. All analyses are reported in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT01817452, and is closed to recruitment.
Between March 3, 2014, and Oct 6, 2015, 134 patients were recruited and randomly assigned to treatment, 92 to trastuzumab plus pertuzumab and 42 to trastuzumab plus pertuzumab plus paclitaxel. Median follow-up in survivors was 59·9 months (IQR 53·4–61·4). There were no significant differences between the treatment groups in invasive disease-free survival, relapse-free survival, locoregional relapse-free survival, distant disease-free survival, and overall survival. In the trastuzumab plus pertuzumab plus paclitaxel group and in the trastuzumab plus pertuzumab group, the proportions of patients achieving 5-year survival respectively were 98% (95% CI 84–100) and 87% (78–93) for invasive disease-free survival (hazard ratio [HR] 0·32, 95% CI 0·07–1·49; p=0·15); 98% (95% CI 84–100) and 89% (79–94) for relapse-free survival (HR 0·41, 95% CI 0·09–1·91; p=0·25); 100% (95% CI not estimable) and 95% (88–98) for locoregional relapse-free survival (HR 0·41, 95% CI 0·05–3·75; p=0·43); 98% (95% CI 84–100) and 92% (83–96) for distant disease-free survival (HR 0·35, 95% CI 0·04–3·12; p=0·36), and 98% (95% CI 84–100) and 94% (86–97) for overall survival (HR 0·41, 95% CI 0·05–3·63; p=0·43). Pathological complete response was associated with improved invasive disease-free survival (HR 0·14, 95% CI 0·03–0·64; p=0·011). Two invasive disease-free survival events occurred after a pathological complete response (one in each treatment group).
The WSG-ADAPT-HER2+/HR– trial showed good survival rates in patients with a pathological complete response after de-escalated 12-week trastuzumab plus pertuzumab with or without weekly paclitaxel. Omission of further chemotherapy did not affect invasive disease-free survival in patients with a pathological complete response. 12 weeks of weekly paclitaxel plus dual HER2 blockade could be an efficacious de-escalated neoadjuvant regimen in patients with hormone receptor-negative, HER2-positive early breast cancer with high pathological complete response rates and good 5-year outcomes. Further trials of this approach are ongoing.
Roche, Bayer.
For the German translation of the abstract see Supplementary Materials section. Several de-escalation neoadjuvant strategies have been investigated to reduce the use of chemotherapy in HER2-positive early breast cancer using pathological complete response as a surrogate endpoint; there are few survival data from these trials. Here, we report 5-year survival data in the WSG-ADAPT-HER2+/HR- trial and address the effect of pathological complete response, early therapy response, and molecular subtype.BACKGROUNDSeveral de-escalation neoadjuvant strategies have been investigated to reduce the use of chemotherapy in HER2-positive early breast cancer using pathological complete response as a surrogate endpoint; there are few survival data from these trials. Here, we report 5-year survival data in the WSG-ADAPT-HER2+/HR- trial and address the effect of pathological complete response, early therapy response, and molecular subtype.WSG-ASAPT-HER2+/HR-, a part of the ADAPT umbrella trial performed in patients with different subtypes of early breast cancer, was an investigator-initiated, multicentre, open-label, randomised, phase 2 trial done at 40 Breast Cancer Centres in Germany. Eligible patients were aged 18 years or older with histologically confirmed, unilateral, primary invasive, non-inflammatory early breast cancer, hormone receptor-negative and HER2-positive status, and an Eastern Cooperative Oncology Group performance status of 0 or 1 or a Karnofsky performance status of at least 80%. Patients were randomly assigned (5:2, block size 21, stratified by centre and clinical nodal status) to 12 weeks of either trastuzumab (8 mg/kg loading dose, then 6 mg/kg every 3 weeks) plus pertuzumab (840 mg loading dose, then 420 mg every 3 weeks) or trastuzumab plus pertuzumab plus paclitaxel (80 mg/m2 weekly); all drugs were administered intravenously. The primary objective of the trial was to compare the number of patients with a pathological complete response at surgery (ie, no invasive tumour cells in breast and lymph nodes [ypT0/is ypN0], the primary endpoint) in early responders (ie, low cellularity or Ki67 decrease ≥30% after 3 weeks) in the trastuzumab plus pertuzumab group versus all patients (irrespective of an early response) in the trastuzumab plus pertuzumab plus paclitaxel group. Non-inferiority was defined as a pathological complete response no worse than 23% lower in the early-responder proportion of patients in the trastuzumab plus pertuzumab group than in the entire trastuzumab plus pertuzumab plus paclitaxel group. The primary endpoint has been reported previously. Additionally, the primary objective of the ADAPT umbrella trial was the evaluation of the effect of pathological complete response on invasive disease-free survival. At investigator's discretion, further chemotherapy could be omitted in patients with a pathological complete response. Secondary survival endpoints were 5-year invasive disease-free survival, relapse-free survival, locoregional relapse-free survival, distant disease-free survival, and overall survival. The effect of pathological complete response on survival was estimated by Cox regression analysis. All analyses are reported in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT01817452, and is closed to recruitment.METHODSWSG-ASAPT-HER2+/HR-, a part of the ADAPT umbrella trial performed in patients with different subtypes of early breast cancer, was an investigator-initiated, multicentre, open-label, randomised, phase 2 trial done at 40 Breast Cancer Centres in Germany. Eligible patients were aged 18 years or older with histologically confirmed, unilateral, primary invasive, non-inflammatory early breast cancer, hormone receptor-negative and HER2-positive status, and an Eastern Cooperative Oncology Group performance status of 0 or 1 or a Karnofsky performance status of at least 80%. Patients were randomly assigned (5:2, block size 21, stratified by centre and clinical nodal status) to 12 weeks of either trastuzumab (8 mg/kg loading dose, then 6 mg/kg every 3 weeks) plus pertuzumab (840 mg loading dose, then 420 mg every 3 weeks) or trastuzumab plus pertuzumab plus paclitaxel (80 mg/m2 weekly); all drugs were administered intravenously. The primary objective of the trial was to compare the number of patients with a pathological complete response at surgery (ie, no invasive tumour cells in breast and lymph nodes [ypT0/is ypN0], the primary endpoint) in early responders (ie, low cellularity or Ki67 decrease ≥30% after 3 weeks) in the trastuzumab plus pertuzumab group versus all patients (irrespective of an early response) in the trastuzumab plus pertuzumab plus paclitaxel group. Non-inferiority was defined as a pathological complete response no worse than 23% lower in the early-responder proportion of patients in the trastuzumab plus pertuzumab group than in the entire trastuzumab plus pertuzumab plus paclitaxel group. The primary endpoint has been reported previously. Additionally, the primary objective of the ADAPT umbrella trial was the evaluation of the effect of pathological complete response on invasive disease-free survival. At investigator's discretion, further chemotherapy could be omitted in patients with a pathological complete response. Secondary survival endpoints were 5-year invasive disease-free survival, relapse-free survival, locoregional relapse-free survival, distant disease-free survival, and overall survival. The effect of pathological complete response on survival was estimated by Cox regression analysis. All analyses are reported in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT01817452, and is closed to recruitment.Between March 3, 2014, and Oct 6, 2015, 134 patients were recruited and randomly assigned to treatment, 92 to trastuzumab plus pertuzumab and 42 to trastuzumab plus pertuzumab plus paclitaxel. Median follow-up in survivors was 59·9 months (IQR 53·4-61·4). There were no significant differences between the treatment groups in invasive disease-free survival, relapse-free survival, locoregional relapse-free survival, distant disease-free survival, and overall survival. In the trastuzumab plus pertuzumab plus paclitaxel group and in the trastuzumab plus pertuzumab group, the proportions of patients achieving 5-year survival respectively were 98% (95% CI 84-100) and 87% (78-93) for invasive disease-free survival (hazard ratio [HR] 0·32, 95% CI 0·07-1·49; p=0·15); 98% (95% CI 84-100) and 89% (79-94) for relapse-free survival (HR 0·41, 95% CI 0·09-1·91; p=0·25); 100% (95% CI not estimable) and 95% (88-98) for locoregional relapse-free survival (HR 0·41, 95% CI 0·05-3·75; p=0·43); 98% (95% CI 84-100) and 92% (83-96) for distant disease-free survival (HR 0·35, 95% CI 0·04-3·12; p=0·36), and 98% (95% CI 84-100) and 94% (86-97) for overall survival (HR 0·41, 95% CI 0·05-3·63; p=0·43). Pathological complete response was associated with improved invasive disease-free survival (HR 0·14, 95% CI 0·03-0·64; p=0·011). Two invasive disease-free survival events occurred after a pathological complete response (one in each treatment group).FINDINGSBetween March 3, 2014, and Oct 6, 2015, 134 patients were recruited and randomly assigned to treatment, 92 to trastuzumab plus pertuzumab and 42 to trastuzumab plus pertuzumab plus paclitaxel. Median follow-up in survivors was 59·9 months (IQR 53·4-61·4). There were no significant differences between the treatment groups in invasive disease-free survival, relapse-free survival, locoregional relapse-free survival, distant disease-free survival, and overall survival. In the trastuzumab plus pertuzumab plus paclitaxel group and in the trastuzumab plus pertuzumab group, the proportions of patients achieving 5-year survival respectively were 98% (95% CI 84-100) and 87% (78-93) for invasive disease-free survival (hazard ratio [HR] 0·32, 95% CI 0·07-1·49; p=0·15); 98% (95% CI 84-100) and 89% (79-94) for relapse-free survival (HR 0·41, 95% CI 0·09-1·91; p=0·25); 100% (95% CI not estimable) and 95% (88-98) for locoregional relapse-free survival (HR 0·41, 95% CI 0·05-3·75; p=0·43); 98% (95% CI 84-100) and 92% (83-96) for distant disease-free survival (HR 0·35, 95% CI 0·04-3·12; p=0·36), and 98% (95% CI 84-100) and 94% (86-97) for overall survival (HR 0·41, 95% CI 0·05-3·63; p=0·43). Pathological complete response was associated with improved invasive disease-free survival (HR 0·14, 95% CI 0·03-0·64; p=0·011). Two invasive disease-free survival events occurred after a pathological complete response (one in each treatment group).The WSG-ADAPT-HER2+/HR- trial showed good survival rates in patients with a pathological complete response after de-escalated 12-week trastuzumab plus pertuzumab with or without weekly paclitaxel. Omission of further chemotherapy did not affect invasive disease-free survival in patients with a pathological complete response. 12 weeks of weekly paclitaxel plus dual HER2 blockade could be an efficacious de-escalated neoadjuvant regimen in patients with hormone receptor-negative, HER2-positive early breast cancer with high pathological complete response rates and good 5-year outcomes. Further trials of this approach are ongoing.INTERPRETATIONThe WSG-ADAPT-HER2+/HR- trial showed good survival rates in patients with a pathological complete response after de-escalated 12-week trastuzumab plus pertuzumab with or without weekly paclitaxel. Omission of further chemotherapy did not affect invasive disease-free survival in patients with a pathological complete response. 12 weeks of weekly paclitaxel plus dual HER2 blockade could be an efficacious de-escalated neoadjuvant regimen in patients with hormone receptor-negative, HER2-positive early breast cancer with high pathological complete response rates and good 5-year outcomes. Further trials of this approach are ongoing.Roche, Bayer.FUNDINGRoche, Bayer.For the German translation of the abstract see Supplementary Materials section.TRANSLATIONFor the German translation o Several de-escalation neoadjuvant strategies have been investigated to reduce the use of chemotherapy in HER2-positive early breast cancer using pathological complete response as a surrogate endpoint; there are few survival data from these trials. Here, we report 5-year survival data in the WSG-ADAPT-HER2+/HR- trial and address the effect of pathological complete response, early therapy response, and molecular subtype. WSG-ASAPT-HER2+/HR-, a part of the ADAPT umbrella trial performed in patients with different subtypes of early breast cancer, was an investigator-initiated, multicentre, open-label, randomised, phase 2 trial done at 40 Breast Cancer Centres in Germany. Eligible patients were aged 18 years or older with histologically confirmed, unilateral, primary invasive, non-inflammatory early breast cancer, hormone receptor-negative and HER2-positive status, and an Eastern Cooperative Oncology Group performance status of 0 or 1 or a Karnofsky performance status of at least 80%. Patients were randomly assigned (5:2, block size 21, stratified by centre and clinical nodal status) to 12 weeks of either trastuzumab (8 mg/kg loading dose, then 6 mg/kg every 3 weeks) plus pertuzumab (840 mg loading dose, then 420 mg every 3 weeks) or trastuzumab plus pertuzumab plus paclitaxel (80 mg/m weekly); all drugs were administered intravenously. The primary objective of the trial was to compare the number of patients with a pathological complete response at surgery (ie, no invasive tumour cells in breast and lymph nodes [ypT0/is ypN0], the primary endpoint) in early responders (ie, low cellularity or Ki67 decrease ≥30% after 3 weeks) in the trastuzumab plus pertuzumab group versus all patients (irrespective of an early response) in the trastuzumab plus pertuzumab plus paclitaxel group. Non-inferiority was defined as a pathological complete response no worse than 23% lower in the early-responder proportion of patients in the trastuzumab plus pertuzumab group than in the entire trastuzumab plus pertuzumab plus paclitaxel group. The primary endpoint has been reported previously. Additionally, the primary objective of the ADAPT umbrella trial was the evaluation of the effect of pathological complete response on invasive disease-free survival. At investigator's discretion, further chemotherapy could be omitted in patients with a pathological complete response. Secondary survival endpoints were 5-year invasive disease-free survival, relapse-free survival, locoregional relapse-free survival, distant disease-free survival, and overall survival. The effect of pathological complete response on survival was estimated by Cox regression analysis. All analyses are reported in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT01817452, and is closed to recruitment. Between March 3, 2014, and Oct 6, 2015, 134 patients were recruited and randomly assigned to treatment, 92 to trastuzumab plus pertuzumab and 42 to trastuzumab plus pertuzumab plus paclitaxel. Median follow-up in survivors was 59·9 months (IQR 53·4-61·4). There were no significant differences between the treatment groups in invasive disease-free survival, relapse-free survival, locoregional relapse-free survival, distant disease-free survival, and overall survival. In the trastuzumab plus pertuzumab plus paclitaxel group and in the trastuzumab plus pertuzumab group, the proportions of patients achieving 5-year survival respectively were 98% (95% CI 84-100) and 87% (78-93) for invasive disease-free survival (hazard ratio [HR] 0·32, 95% CI 0·07-1·49; p=0·15); 98% (95% CI 84-100) and 89% (79-94) for relapse-free survival (HR 0·41, 95% CI 0·09-1·91; p=0·25); 100% (95% CI not estimable) and 95% (88-98) for locoregional relapse-free survival (HR 0·41, 95% CI 0·05-3·75; p=0·43); 98% (95% CI 84-100) and 92% (83-96) for distant disease-free survival (HR 0·35, 95% CI 0·04-3·12; p=0·36), and 98% (95% CI 84-100) and 94% (86-97) for overall survival (HR 0·41, 95% CI 0·05-3·63; p=0·43). Pathological complete response was associated with improved invasive disease-free survival (HR 0·14, 95% CI 0·03-0·64; p=0·011). Two invasive disease-free survival events occurred after a pathological complete response (one in each treatment group). The WSG-ADAPT-HER2+/HR- trial showed good survival rates in patients with a pathological complete response after de-escalated 12-week trastuzumab plus pertuzumab with or without weekly paclitaxel. Omission of further chemotherapy did not affect invasive disease-free survival in patients with a pathological complete response. 12 weeks of weekly paclitaxel plus dual HER2 blockade could be an efficacious de-escalated neoadjuvant regimen in patients with hormone receptor-negative, HER2-positive early breast cancer with high pathological complete response rates and good 5-year outcomes. Further trials of this approach are ongoing. Roche, Bayer. For the German translation of the abstract see Supplementary Materials section. SummaryBackgroundSeveral de-escalation neoadjuvant strategies have been investigated to reduce the use of chemotherapy in HER2-positive early breast cancer using pathological complete response as a surrogate endpoint; there are few survival data from these trials. Here, we report 5-year survival data in the WSG-ADAPT-HER2+/HR– trial and address the effect of pathological complete response, early therapy response, and molecular subtype. MethodsWSG-ASAPT-HER2+/HR–, a part of the ADAPT umbrella trial performed in patients with different subtypes of early breast cancer, was an investigator-initiated, multicentre, open-label, randomised, phase 2 trial done at 40 Breast Cancer Centres in Germany. Eligible patients were aged 18 years or older with histologically confirmed, unilateral, primary invasive, non-inflammatory early breast cancer, hormone receptor-negative and HER2-positive status, and an Eastern Cooperative Oncology Group performance status of 0 or 1 or a Karnofsky performance status of at least 80%. Patients were randomly assigned (5:2, block size 21, stratified by centre and clinical nodal status) to 12 weeks of either trastuzumab (8 mg/kg loading dose, then 6 mg/kg every 3 weeks) plus pertuzumab (840 mg loading dose, then 420 mg every 3 weeks) or trastuzumab plus pertuzumab plus paclitaxel (80 mg/m 2 weekly); all drugs were administered intravenously. The primary objective of the trial was to compare the number of patients with a pathological complete response at surgery (ie, no invasive tumour cells in breast and lymph nodes [ypT0/is ypN0], the primary endpoint) in early responders (ie, low cellularity or Ki67 decrease ≥30% after 3 weeks) in the trastuzumab plus pertuzumab group versus all patients (irrespective of an early response) in the trastuzumab plus pertuzumab plus paclitaxel group. Non-inferiority was defined as a pathological complete response no worse than 23% lower in the early-responder proportion of patients in the trastuzumab plus pertuzumab group than in the entire trastuzumab plus pertuzumab plus paclitaxel group. The primary endpoint has been reported previously. Additionally, the primary objective of the ADAPT umbrella trial was the evaluation of the effect of pathological complete response on invasive disease-free survival. At investigator's discretion, further chemotherapy could be omitted in patients with a pathological complete response. Secondary survival endpoints were 5-year invasive disease-free survival, relapse-free survival, locoregional relapse-free survival, distant disease-free survival, and overall survival. The effect of pathological complete response on survival was estimated by Cox regression analysis. All analyses are reported in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT01817452, and is closed to recruitment. FindingsBetween March 3, 2014, and Oct 6, 2015, 134 patients were recruited and randomly assigned to treatment, 92 to trastuzumab plus pertuzumab and 42 to trastuzumab plus pertuzumab plus paclitaxel. Median follow-up in survivors was 59·9 months (IQR 53·4–61·4). There were no significant differences between the treatment groups in invasive disease-free survival, relapse-free survival, locoregional relapse-free survival, distant disease-free survival, and overall survival. In the trastuzumab plus pertuzumab plus paclitaxel group and in the trastuzumab plus pertuzumab group, the proportions of patients achieving 5-year survival respectively were 98% (95% CI 84–100) and 87% (78–93) for invasive disease-free survival (hazard ratio [HR] 0·32, 95% CI 0·07–1·49; p=0·15); 98% (95% CI 84–100) and 89% (79–94) for relapse-free survival (HR 0·41, 95% CI 0·09–1·91; p=0·25); 100% (95% CI not estimable) and 95% (88–98) for locoregional relapse-free survival (HR 0·41, 95% CI 0·05–3·75; p=0·43); 98% (95% CI 84–100) and 92% (83–96) for distant disease-free survival (HR 0·35, 95% CI 0·04–3·12; p=0·36), and 98% (95% CI 84–100) and 94% (86–97) for overall survival (HR 0·41, 95% CI 0·05–3·63; p=0·43). Pathological complete response was associated with improved invasive disease-free survival (HR 0·14, 95% CI 0·03–0·64; p=0·011). Two invasive disease-free survival events occurred after a pathological complete response (one in each treatment group). InterpretationThe WSG-ADAPT-HER2+/HR– trial showed good survival rates in patients with a pathological complete response after de-escalated 12-week trastuzumab plus pertuzumab with or without weekly paclitaxel. Omission of further chemotherapy did not affect invasive disease-free survival in patients with a pathological complete response. 12 weeks of weekly paclitaxel plus dual HER2 blockade could be an efficacious de-escalated neoadjuvant regimen in patients with hormone receptor-negative, HER2-positive early breast cancer with high pathological complete response rates and good 5-year outcomes. Further trials of this approach are ongoing. FundingRoche, Bayer. TranslationFor the German translation of the abstract see Supplementary Materials section. Summary Background Several de-escalation neoadjuvant strategies have been investigated to reduce the use of chemotherapy in HER2-positive early breast cancer using pathological complete response as a surrogate endpoint; there are few survival data from these trials. Here, we report 5-year survival data in the WSG-ADAPT-HER2+/HR– trial and address the effect of pathological complete response, early therapy response, and molecular subtype. Methods WSG-ASAPT-HER2+/HR–, a part of the ADAPT umbrella trial performed in patients with different subtypes of early breast cancer, was an investigator-initiated, multicentre, open-label, randomised, phase 2 trial done at 40 Breast Cancer Centres in Germany. Eligible patients were aged 18 years or older with histologically confirmed, unilateral, primary invasive, non-inflammatory early breast cancer, hormone receptor-negative and HER2-positive status, and an Eastern Cooperative Oncology Group performance status of 0 or 1 or a Karnofsky performance status of at least 80%. Patients were randomly assigned (5:2, block size 21, stratified by centre and clinical nodal status) to 12 weeks of either trastuzumab (8 mg/kg loading dose, then 6 mg/kg every 3 weeks) plus pertuzumab (840 mg loading dose, then 420 mg every 3 weeks) or trastuzumab plus pertuzumab plus paclitaxel (80 mg/m2 weekly); all drugs were administered intravenously. The primary objective of the trial was to compare the number of patients with a pathological complete response at surgery (ie, no invasive tumour cells in breast and lymph nodes [ypT0/is ypN0], the primary endpoint) in early responders (ie, low cellularity or Ki67 decrease ≥30% after 3 weeks) in the trastuzumab plus pertuzumab group versus all patients (irrespective of an early response) in the trastuzumab plus pertuzumab plus paclitaxel group. Non-inferiority was defined as a pathological complete response no worse than 23% lower in the early-responder proportion of patients in the trastuzumab plus pertuzumab group than in the entire trastuzumab plus pertuzumab plus paclitaxel group. The primary endpoint has been reported previously. Additionally, the primary objective of the ADAPT umbrella trial was the evaluation of the effect of pathological complete response on invasive disease-free survival. At investigator's discretion, further chemotherapy could be omitted in patients with a pathological complete response. Secondary survival endpoints were 5-year invasive disease-free survival, relapse-free survival, locoregional relapse-free survival, distant disease-free survival, and overall survival. The effect of pathological complete response on survival was estimated by Cox regression analysis. All analyses are reported in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT01817452, and is closed to recruitment. Findings Between March 3, 2014, and Oct 6, 2015, 134 patients were recruited and randomly assigned to treatment, 92 to trastuzumab plus pertuzumab and 42 to trastuzumab plus pertuzumab plus paclitaxel. Median follow-up in survivors was 59·9 months (IQR 53·4–61·4). There were no significant differences between the treatment groups in invasive disease-free survival, relapse-free survival, locoregional relapse-free survival, distant disease-free survival, and overall survival. In the trastuzumab plus pertuzumab plus paclitaxel group and in the trastuzumab plus pertuzumab group, the proportions of patients achieving 5-year survival respectively were 98% (95% CI 84–100) and 87% (78–93) for invasive disease-free survival (hazard ratio [HR] 0·32, 95% CI 0·07–1·49; p=0·15); 98% (95% CI 84–100) and 89% (79–94) for relapse-free survival (HR 0·41, 95% CI 0·09–1·91; p=0·25); 100% (95% CI not estimable) and 95% (88–98) for locoregional relapse-free survival (HR 0·41, 95% CI 0·05–3·75; p=0·43); 98% (95% CI 84–100) and 92% (83–96) for distant disease-free survival (HR 0·35, 95% CI 0·04–3·12; p=0·36), and 98% (95% CI 84–100) and 94% (86–97) for overall survival (HR 0·41, 95% CI 0·05–3·63; p=0·43). Pathological complete response was associated with improved invasive disease-free survival (HR 0·14, 95% CI 0·03–0·64; p=0·011). Two invasive disease-free survival events occurred after a pathological complete response (one in each treatment group). Interpretation The WSG-ADAPT-HER2+/HR– trial showed good survival rates in patients with a pathological complete response after de-escalated 12-week trastuzumab plus pertuzumab with or without weekly paclitaxel. Omission of further chemotherapy did not affect invasive disease-free survival in patients with a pathological complete response. 12 weeks of weekly paclitaxel plus dual HER2 blockade could be an efficacious de-escalated neoadjuvant regimen in patients with hormone receptor-negative, HER2-positive early breast cancer with high pathological complete response rates and good 5-year outcomes. Further trials of this approach are ongoing. Funding Roche, Bayer. Translation For the German translation of the abstract see Supplementary Materials section. |
| Author | Kuhn, Walther Just, Marianne Kirchhof, Heidrun Christgen, Matthias Fischer, Hans Holger Krabisch, Petra Krauss, Katja Reimer, Toralf Harbeck, Nadia Lindner, Christoph Nitz, Ulrike Graeser, Monika Wuerstlein, Rachel Siggelkow, Wulf Kuemmel, Sherko Wortelmann, Heidi Staib, Peter Link, Theresa Forstbauer, Helmut Leitzen, Lena Polata, Silke Bauer, Leila Schumacher, Claudia Gnauert, Karsten Kleine-Tebbe, Anke Malter, Wolfram Mohrmann, Svjetlana Stefek, Andrea Lehnert, Antje Pelz, Enrico Hackmann, John Viehstaedt, Nicole Bielecki, Wojciech Meyer, Ralf Kreipe, Hans Heinrich zu Eulenburg, Christine Gluz, Oleg Augustin, Doris Buendgen, Nana Kraudelt, Susanne Kates, Ronald Braun, Michael Hoffmann, Oliver Potenberg, Jochem Uleer, Christoph von Schumann, Raquel Grischke, Eva-Maria Tio, Joke Briest, Susanne Depenbusch, Reinhard Heyl, Volker |
| Author_xml | – sequence: 1 givenname: Ulrike surname: Nitz fullname: Nitz, Ulrike organization: West German Study Group, Moenchengladbach, Germany – sequence: 2 givenname: Oleg surname: Gluz fullname: Gluz, Oleg organization: West German Study Group, Moenchengladbach, Germany – sequence: 3 givenname: Monika surname: Graeser fullname: Graeser, Monika organization: West German Study Group, Moenchengladbach, Germany – sequence: 4 givenname: Matthias surname: Christgen fullname: Christgen, Matthias organization: Institute of Pathology, Medical School Hannover, Hannover, Germany – sequence: 5 givenname: Sherko surname: Kuemmel fullname: Kuemmel, Sherko organization: West German Study Group, Moenchengladbach, Germany – sequence: 6 givenname: Eva-Maria surname: Grischke fullname: Grischke, Eva-Maria organization: Women's Clinic, University Clinics Tuebingen, Tuebingen, Germany – sequence: 7 givenname: Michael surname: Braun fullname: Braun, Michael organization: Breast Center, Rotkreuz Clinics Munich, Munich, Germany – sequence: 8 givenname: Doris surname: Augustin fullname: Augustin, Doris organization: Breast Center Ostbayern, Deggendorf, Germany – sequence: 9 givenname: Jochem surname: Potenberg fullname: Potenberg, Jochem organization: Ev Waldkrankenhaus Berlin, Berlin, Germany – sequence: 10 givenname: Katja surname: Krauss fullname: Krauss, Katja organization: University Clinics Aachen, Women's Clinic, Aachen, Germany – sequence: 11 givenname: Claudia surname: Schumacher fullname: Schumacher, Claudia organization: Breast Center, St Elisabeth Hospital, Cologne, Germany – sequence: 12 givenname: Helmut surname: Forstbauer fullname: Forstbauer, Helmut organization: Oncology Practice Network Troisdorf, Troisdorf, Germany – sequence: 13 givenname: Toralf surname: Reimer fullname: Reimer, Toralf organization: University Hospital Gynecology and Policlinic Rostock, Rostock, Germany – sequence: 14 givenname: Andrea surname: Stefek fullname: Stefek, Andrea organization: Breast Center, Evangelical Hospital Johanniter, Stendal, Germany – sequence: 15 givenname: Hans Holger surname: Fischer fullname: Fischer, Hans Holger organization: Breast Center, Evangelical Hospital Gelsenkirchen, Gelsenkirchen, Germany – sequence: 16 givenname: Enrico surname: Pelz fullname: Pelz, Enrico organization: Institute for Pathology, Viersen, Germany – sequence: 17 givenname: Christine surname: zu Eulenburg fullname: zu Eulenburg, Christine organization: West German Study Group, Moenchengladbach, Germany – sequence: 18 givenname: Ronald surname: Kates fullname: Kates, Ronald organization: West German Study Group, Moenchengladbach, Germany – sequence: 19 givenname: Rachel surname: Wuerstlein fullname: Wuerstlein, Rachel organization: West German Study Group, Moenchengladbach, Germany – sequence: 20 givenname: Hans Heinrich surname: Kreipe fullname: Kreipe, Hans Heinrich organization: Institute of Pathology, Medical School Hannover, Hannover, Germany – sequence: 21 givenname: Nadia surname: Harbeck fullname: Harbeck, Nadia email: nadia.harbeck@med.uni-muenchen.de organization: West German Study Group, Moenchengladbach, Germany – sequence: 22 givenname: Raquel surname: von Schumann fullname: von Schumann, Raquel – sequence: 23 givenname: Walther surname: Kuhn fullname: Kuhn, Walther – sequence: 24 givenname: Silke surname: Polata fullname: Polata, Silke – sequence: 25 givenname: Wojciech surname: Bielecki fullname: Bielecki, Wojciech – sequence: 26 givenname: Ralf surname: Meyer fullname: Meyer, Ralf – sequence: 27 givenname: Marianne surname: Just fullname: Just, Marianne – sequence: 28 givenname: Susanne surname: Kraudelt fullname: Kraudelt, Susanne – sequence: 29 givenname: Wulf surname: Siggelkow fullname: Siggelkow, Wulf – sequence: 30 givenname: Heidi surname: Wortelmann fullname: Wortelmann, Heidi – sequence: 31 givenname: Anke surname: Kleine-Tebbe fullname: Kleine-Tebbe, Anke – sequence: 32 givenname: Lena surname: Leitzen fullname: Leitzen, Lena – sequence: 33 givenname: Heidrun surname: Kirchhof fullname: Kirchhof, Heidrun – sequence: 34 givenname: Petra surname: Krabisch fullname: Krabisch, Petra – sequence: 35 givenname: John surname: Hackmann fullname: Hackmann, John – sequence: 36 givenname: Reinhard surname: Depenbusch fullname: Depenbusch, Reinhard – sequence: 37 givenname: Karsten surname: Gnauert fullname: Gnauert, Karsten – sequence: 38 givenname: Peter surname: Staib fullname: Staib, Peter – sequence: 39 givenname: Antje surname: Lehnert fullname: Lehnert, Antje – sequence: 40 givenname: Oliver surname: Hoffmann fullname: Hoffmann, Oliver – sequence: 41 givenname: Susanne surname: Briest fullname: Briest, Susanne – sequence: 42 givenname: Christoph surname: Lindner fullname: Lindner, Christoph – sequence: 43 givenname: Volker surname: Heyl fullname: Heyl, Volker – sequence: 44 givenname: Leila surname: Bauer fullname: Bauer, Leila – sequence: 45 givenname: Christoph surname: Uleer fullname: Uleer, Christoph – sequence: 46 givenname: Svjetlana surname: Mohrmann fullname: Mohrmann, Svjetlana – sequence: 47 givenname: Nicole surname: Viehstaedt fullname: Viehstaedt, Nicole – sequence: 48 givenname: Wolfram surname: Malter fullname: Malter, Wolfram – sequence: 49 givenname: Theresa surname: Link fullname: Link, Theresa – sequence: 50 givenname: Nana surname: Buendgen fullname: Buendgen, Nana – sequence: 51 givenname: Joke surname: Tio fullname: Tio, Joke |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35405088$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkt1u1DAQhQMqoj_wCCBL3LRiQx0nzg8IUNWWLlIlUFvEpeV1ZllvnTjYzpblinfgDXkSJrttLyqhchNH9neOxzNnO9pobQtR9CyhrxKa5PvnSVbQmNGM7zK2R2nCq5g-jLZwO4t5VpYbq_81shltez9HqEgofxxtpjyjnJbl1oONI4jBK2lkgJq0YGU97xeyDaQDF_qffSMnpDO9J8FJf7MRZuBktyRXOsyIdavV9oFcAVyaJemkMjrIH2CIbsn4-IzFnfU66AWMyMy6Bp9CHCjognVxC9_k-gikQ_XEAd5ElGwVOLL79fwkPjg6-HwRD0Yv98dnf3793ntNfO8WeiENwYuVbcCTqbMNkaTpTdAK2uDQ0nbQxkZOwIyIk21tG-2hHpFuJj0Qhq_S0jyJHk2l8fD0et2Jvnw4vjgcx6efTj4eHpzGilMW4gpKWdQy4wXj06JQKq8ntFaMUVVWWZLytJokkLOkzMu0TAuZIZzmkBZZldZTSHei3bVv5-z3HnwQWI0CYyQ2vveC5VnFK8Z4guiLO-jc9q7F6pDieYKfbKCeX1P9pIFadE430i3FzXwR4GtAOeu9g-ktklAx5EisciSGkAjGxCpHgqLuzR2dwoEGbbGrUpt71e_XasBmLjQ44ZUGHGetcepB1Fbf6_DujgMmqtWY00tYgr_tRSI8itYmgwfOYnAYDN7-2-A_CvgLGDEMEQ |
| CitedBy_id | crossref_primary_10_3390_curroncol30080545 crossref_primary_10_3389_fonc_2024_1281643 crossref_primary_10_1016_j_annonc_2023_11_016 crossref_primary_10_1038_s41392_024_02108_4 crossref_primary_10_1245_s10434_024_16190_z crossref_primary_10_3390_cancers14205027 crossref_primary_10_1007_s10549_024_07333_7 crossref_primary_10_1016_j_clbc_2023_07_006 crossref_primary_10_3390_cancers14123002 crossref_primary_10_1016_j_breast_2025_104461 crossref_primary_10_1177_17588359231225032 crossref_primary_10_1016_j_senol_2024_100659 crossref_primary_10_1200_EDBK_432442 crossref_primary_10_1016_S1470_2045_24_00104_9 crossref_primary_10_3390_cancers14163949 crossref_primary_10_1158_1078_0432_CCR_24_0464 crossref_primary_10_1097_XCS_0000000000000761 crossref_primary_10_1016_j_ejrad_2023_111050 crossref_primary_10_1016_j_ejca_2023_03_042 crossref_primary_10_1007_s12254_023_00942_w crossref_primary_10_1016_j_breast_2023_03_001 crossref_primary_10_1016_j_annonc_2023_05_012 crossref_primary_10_1038_s41392_025_02138_6 crossref_primary_10_1007_s11864_024_01252_x crossref_primary_10_1016_j_trecan_2023_11_001 crossref_primary_10_1055_a_1921_9336 crossref_primary_10_1038_s41571_024_00939_2 crossref_primary_10_1097_XCS_0000000000000719 crossref_primary_10_1158_1078_0432_CCR_22_1587 crossref_primary_10_1186_s12880_024_01518_8 crossref_primary_10_1016_j_acra_2025_01_016 crossref_primary_10_3390_cancers16061121 crossref_primary_10_1007_s11864_023_01070_7 crossref_primary_10_18027_2224_5057_2023_13_3_29_36 crossref_primary_10_1039_D2TB02328H crossref_primary_10_1186_s40001_024_02188_6 crossref_primary_10_3390_cancers16203478 crossref_primary_10_1016_j_clbc_2024_03_004 crossref_primary_10_1186_s12885_023_11719_z crossref_primary_10_2967_jnumed_123_265853 crossref_primary_10_1016_j_ebiom_2022_104320 crossref_primary_10_3389_fonc_2023_1066007 crossref_primary_10_1001_jamaoncol_2024_5371 |
| Cites_doi | 10.1093/annonc/mdx494 10.1016/S1470-2045(11)70336-9 10.1200/JCO.2012.44.8027 10.1158/2159-8290.CD-20-1557 10.1093/annonc/mdx647 10.1093/annonc/mdv106 10.1158/1538-7445.SABCS19-P4-10-05 10.1200/JCO.2020.38.15_suppl.515 10.1016/S0140-6736(13)62422-8 10.1093/jnci/djz042 10.1093/annonc/mdz055 10.1001/jamaoncol.2015.6113 10.1016/S1470-2045(17)30021-9 10.1200/JCO.2013.50.9984 10.1002/ijc.33495 10.1200/OP.21.00020 10.1001/jamaoncol.2021.1371 10.1016/S1470-2045(21)00122-4 10.1200/JCO.20.01276 10.1016/j.ejca.2012.05.023 10.1002/ijc.32488 10.1186/s13058-021-01413-y 10.1158/1538-7445.SABCS20-PD3-05 10.1200/JCO.18.01842 10.1158/1078-0432.CCR-19-0851 |
| ContentType | Journal Article |
| Contributor | Kuhn, Walther Malter, Wolfram Just, Marianne Mohrmann, Svjetlana Kirchhof, Heidrun Lehnert, Antje Krabisch, Petra Lindner, Christoph Hackmann, John Viehstaedt, Nicole Bielecki, Wojciech Meyer, Ralf Siggelkow, Wulf Buendgen, Nana Wortelmann, Heidi Staib, Peter Kraudelt, Susanne Hoffmann, Oliver Link, Theresa Uleer, Christoph von Schumann, Raquel Leitzen, Lena Tio, Joke Polata, Silke Briest, Susanne Depenbusch, Reinhard Heyl, Volker Bauer, Leila Gnauert, Karsten Kleine-Tebbe, Anke |
| Contributor_xml | – sequence: 1 givenname: Raquel surname: von Schumann fullname: von Schumann, Raquel – sequence: 2 givenname: Walther surname: Kuhn fullname: Kuhn, Walther – sequence: 3 givenname: Silke surname: Polata fullname: Polata, Silke – sequence: 4 givenname: Wojciech surname: Bielecki fullname: Bielecki, Wojciech – sequence: 5 givenname: Ralf surname: Meyer fullname: Meyer, Ralf – sequence: 6 givenname: Marianne surname: Just fullname: Just, Marianne – sequence: 7 givenname: Susanne surname: Kraudelt fullname: Kraudelt, Susanne – sequence: 8 givenname: Wulf surname: Siggelkow fullname: Siggelkow, Wulf – sequence: 9 givenname: Heidi surname: Wortelmann fullname: Wortelmann, Heidi – sequence: 10 givenname: Anke surname: Kleine-Tebbe fullname: Kleine-Tebbe, Anke – sequence: 11 givenname: Lena surname: Leitzen fullname: Leitzen, Lena – sequence: 12 givenname: Heidrun surname: Kirchhof fullname: Kirchhof, Heidrun – sequence: 13 givenname: Petra surname: Krabisch fullname: Krabisch, Petra – sequence: 14 givenname: John surname: Hackmann fullname: Hackmann, John – sequence: 15 givenname: Reinhard surname: Depenbusch fullname: Depenbusch, Reinhard – sequence: 16 givenname: Karsten surname: Gnauert fullname: Gnauert, Karsten – sequence: 17 givenname: Peter surname: Staib fullname: Staib, Peter – sequence: 18 givenname: Antje surname: Lehnert fullname: Lehnert, Antje – sequence: 19 givenname: Oliver surname: Hoffmann fullname: Hoffmann, Oliver – sequence: 20 givenname: Susanne surname: Briest fullname: Briest, Susanne – sequence: 21 givenname: Christoph surname: Lindner fullname: Lindner, Christoph – sequence: 22 givenname: Volker surname: Heyl fullname: Heyl, Volker – sequence: 23 givenname: Leila surname: Bauer fullname: Bauer, Leila – sequence: 24 givenname: Christoph surname: Uleer fullname: Uleer, Christoph – sequence: 25 givenname: Svjetlana surname: Mohrmann fullname: Mohrmann, Svjetlana – sequence: 26 givenname: Nicole surname: Viehstaedt fullname: Viehstaedt, Nicole – sequence: 27 givenname: Wolfram surname: Malter fullname: Malter, Wolfram – sequence: 28 givenname: Theresa surname: Link fullname: Link, Theresa – sequence: 29 givenname: Nana surname: Buendgen fullname: Buendgen, Nana – sequence: 30 givenname: Joke surname: Tio fullname: Tio, Joke |
| Copyright | 2022 Elsevier Ltd Elsevier Ltd Copyright © 2022 Elsevier Ltd. All rights reserved. 2022. Elsevier Ltd |
| Copyright_xml | – notice: 2022 Elsevier Ltd – notice: Elsevier Ltd – notice: Copyright © 2022 Elsevier Ltd. All rights reserved. – notice: 2022. Elsevier Ltd |
| CorporateAuthor | WSG-ADAPT investigators |
| CorporateAuthor_xml | – name: WSG-ADAPT investigators |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 0TZ 3V. 7RV 7TO 7X7 7XB 88E 8AO 8C1 8C2 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH H94 K9. KB0 M0S M1P NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 |
| DOI | 10.1016/S1470-2045(22)00159-0 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Pharma and Biotech Premium PRO ProQuest Central (Corporate) Nursing & Allied Health Database Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Lancet Titles Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Health & Medical Collection (Alumni) Medical Database Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Pharma and Biotech Premium PRO Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) Lancet Titles ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE Pharma and Biotech Premium PRO |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1474-5488 |
| EndPage | 635 |
| ExternalDocumentID | 35405088 10_1016_S1470_2045_22_00159_0 S1470204522001590 1_s2_0_S1470204522001590 |
| Genre | Multicenter Study Clinical Trial, Phase II Randomized Controlled Trial Journal Article |
| GeographicLocations | Germany |
| GeographicLocations_xml | – name: Germany |
| GrantInformation | Roche, Bayer. |
| GroupedDBID | --- --K --M -RU .1- .55 .FO 0R~ 123 1B1 1P~ 1~5 29L 4.4 457 4CK 4G. 53G 5VS 6PF 7-5 71M 7RV 7X7 88E 8AO 8C1 8C2 8FI 8FJ AAEDT AAEDW AAIKJ AAKOC AALRI AAMRU AAQFI AAQQT AAQXK AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABMAC ABMZM ABUWG ABWVN ACGFS ACIEU ACPRK ACRLP ACRPL ACVFH ADBBV ADCNI ADMUD ADNMO AEIPS AEKER AENEX AEUPX AEVXI AFKRA AFPUW AFRHN AFTJW AFXIZ AGCQF AGHFR AGQPQ AHMBA AIGII AIIUN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BENPR BKEYQ BKOJK BNPGV BPHCQ BVXVI CCPQU CS3 DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN FYUFA G-Q GBLVA HMCUK HVGLF HZ~ IHE J1W KOM M1P M41 MO0 N9A NAPCQ O-L O9- OC~ OO- OZT P-8 P-9 P2P PCD PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO R2- ROL RPZ SDG SEL SES SPCBC SSH SSZ T5K TLN UKHRP UV1 WOW X7M XBR Z5R 3V. AACTN AFCTW AFKWA AJOXV ALIPV AMFUW RIG SDF ABLVK ABYKQ AHPSJ AJBFU ZA5 AAYXX AGRNS CITATION CGR CUY CVF ECM EIF NPM 0TZ 7TO 7XB 8FK H94 K9. PKEHL PQEST PQUKI PRINS 7X8 |
| ID | FETCH-LOGICAL-c502t-9e8a7da45725f77cc6db0dc220c89413539b1e6218683837a4da436e37493dfe3 |
| IEDL.DBID | 7X7 |
| ISSN | 1470-2045 1474-5488 |
| IngestDate | Thu Sep 04 23:45:26 EDT 2025 Sat Jul 26 00:26:30 EDT 2025 Wed Feb 19 02:26:35 EST 2025 Tue Jul 01 01:53:28 EDT 2025 Thu Apr 24 23:07:47 EDT 2025 Fri Feb 23 02:41:34 EST 2024 Tue Feb 25 20:02:55 EST 2025 Tue Aug 26 16:33:28 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Language | English |
| License | Copyright © 2022 Elsevier Ltd. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c502t-9e8a7da45725f77cc6db0dc220c89413539b1e6218683837a4da436e37493dfe3 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Feature-3 ObjectType-Evidence Based Healthcare-1 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3 |
| PMID | 35405088 |
| PQID | 2656126541 |
| PQPubID | 46089 |
| PageCount | 11 |
| ParticipantIDs | proquest_miscellaneous_2649592251 proquest_journals_2656126541 pubmed_primary_35405088 crossref_primary_10_1016_S1470_2045_22_00159_0 crossref_citationtrail_10_1016_S1470_2045_22_00159_0 elsevier_sciencedirect_doi_10_1016_S1470_2045_22_00159_0 elsevier_clinicalkeyesjournals_1_s2_0_S1470204522001590 elsevier_clinicalkey_doi_10_1016_S1470_2045_22_00159_0 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2022-05-01 |
| PublicationDateYYYYMMDD | 2022-05-01 |
| PublicationDate_xml | – month: 05 year: 2022 text: 2022-05-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | The lancet oncology |
| PublicationTitleAlternate | Lancet Oncol |
| PublicationYear | 2022 |
| Publisher | Elsevier Ltd Elsevier Limited |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier Limited |
| References | Graeser, Schrading, Gluz (bib16) 2021; 23 Prat, Pascual, De Angelis (bib24) 2020; 112 Waks, Desai, Li (bib25) 2021; 81 Llombart-Cussac, Cortés, Paré (bib6) 2017; 18 Untch, Jackisch, Schneeweiss (bib18) 2019; 37 Fernandez-Martinez, Krop, Hillman (bib19) 2020; 38 Houssami, MacAskill, Von Minckwitz, Marinovich, Mamounas (bib3) 2012; 48 Pernas, Tolaney (bib1) 2021; 17 Nuciforo, Pascual, Cortés (bib11) 2018; 29 Gluz, Kolberg-Liedtke, Prat (bib12) 2020; 146 Guarneri, Dieci, Bisagni (bib23) 2019; 30 Gluz, Nitz, Christgen (bib21) 2020; 38 Broglio, Quintana, Foster (bib4) 2016; 2 Rimawi, Niravath, Wang (bib8) 2020; 26 Gluz, Kolberg-Liedtke, Biehl (bib17) 2020; 80 Gourgou-Bourgade, Cameron, Poortmans (bib14) 2015; 26 Rimawi, Mayer, Forero (bib7) 2013; 31 Graeser, Schrading, Gluz (bib15) 2021; 148 Cortazar, Zhang, Untch (bib2) 2014; 384 Wolff, Hammond, Hicks (bib13) 2013; 31 Pérez-García, Gebhart, Ruiz Borrego (bib10) 2021; 22 Filho, Viale, Stein (bib22) 2021; 11 Nitz, Gluz, Christgen (bib9) 2017; 28 Gianni, Pienkowski, Im (bib5) 2012; 13 van der Voort, van Ramshorst, van Werkhoven (bib20) 2021; 7 Gluz (10.1016/S1470-2045(22)00159-0_bib17) 2020; 80 Cortazar (10.1016/S1470-2045(22)00159-0_bib2) 2014; 384 Rimawi (10.1016/S1470-2045(22)00159-0_bib8) 2020; 26 Waks (10.1016/S1470-2045(22)00159-0_bib25) 2021; 81 Nuciforo (10.1016/S1470-2045(22)00159-0_bib11) 2018; 29 Guarneri (10.1016/S1470-2045(22)00159-0_bib23) 2019; 30 Fernandez-Martinez (10.1016/S1470-2045(22)00159-0_bib19) 2020; 38 Pérez-García (10.1016/S1470-2045(22)00159-0_bib10) 2021; 22 Nitz (10.1016/S1470-2045(22)00159-0_bib9) 2017; 28 Broglio (10.1016/S1470-2045(22)00159-0_bib4) 2016; 2 Graeser (10.1016/S1470-2045(22)00159-0_bib15) 2021; 148 Untch (10.1016/S1470-2045(22)00159-0_bib18) 2019; 37 Gluz (10.1016/S1470-2045(22)00159-0_bib21) 2020; 38 Llombart-Cussac (10.1016/S1470-2045(22)00159-0_bib6) 2017; 18 Gluz (10.1016/S1470-2045(22)00159-0_bib12) 2020; 146 Gianni (10.1016/S1470-2045(22)00159-0_bib5) 2012; 13 Prat (10.1016/S1470-2045(22)00159-0_bib24) 2020; 112 Wolff (10.1016/S1470-2045(22)00159-0_bib13) 2013; 31 Gourgou-Bourgade (10.1016/S1470-2045(22)00159-0_bib14) 2015; 26 Rimawi (10.1016/S1470-2045(22)00159-0_bib7) 2013; 31 Pernas (10.1016/S1470-2045(22)00159-0_bib1) 2021; 17 Houssami (10.1016/S1470-2045(22)00159-0_bib3) 2012; 48 Filho (10.1016/S1470-2045(22)00159-0_bib22) 2021; 11 van der Voort (10.1016/S1470-2045(22)00159-0_bib20) 2021; 7 Graeser (10.1016/S1470-2045(22)00159-0_bib16) 2021; 23 |
| References_xml | – volume: 18 start-page: 545 year: 2017 end-page: 554 ident: bib6 article-title: HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial publication-title: Lancet Oncol – volume: 384 start-page: 164 year: 2014 end-page: 172 ident: bib2 article-title: Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis publication-title: Lancet – volume: 29 start-page: 170 year: 2018 end-page: 177 ident: bib11 article-title: A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade publication-title: Ann Oncol – volume: 31 start-page: 1726 year: 2013 end-page: 1731 ident: bib7 article-title: Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2–overexpressing breast cancer: TBCRC 006 publication-title: J Clin Oncol – volume: 11 start-page: 2474 year: 2021 end-page: 2487 ident: bib22 article-title: Impact of HER2 heterogeneity on treatment response of early-stage HER2-positive breast cancer: phase ii neoadjuvant clinical trial of t-DM1 combined with pertuzumab publication-title: Cancer Discov – volume: 80 year: 2020 ident: bib17 article-title: Predictive value of HER2 expression, early response and tumor infiltrating lymphocytes (TILs) on efficacy of de-escalated pertuzumab+trastuzumab in the neoadjuvant WSG-ADAPT-HER2+/HR– trial publication-title: Cancer Res – volume: 26 start-page: 821 year: 2020 end-page: 827 ident: bib8 article-title: TBCRC023: a randomized phase II neoadjuvant trial of lapatinib plus trastuzumab without chemotherapy for 12 versus 24 weeks in patients with HER2-positive breast cancer publication-title: Clin Cancer Res – volume: 28 start-page: 2768 year: 2017 end-page: 2772 ident: bib9 article-title: De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR– phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel publication-title: Ann Oncol – volume: 81 year: 2021 ident: bib25 article-title: The DAPHNE trial: a feasibility study of chemotherapy de-escalation based on response to neoadjuvant paclitaxel-HP (THP) in HER2-positive breast cancer publication-title: Cancer Res – volume: 38 start-page: 515 year: 2020 ident: bib21 article-title: De-escalated chemotherapy versus endocrine therapy plus pertuzumab+ trastuzumab for HR+/HER2+ early breast cancer (BC): first efficacy results from the neoadjuvant WSG-TP-II study publication-title: Proc Am Soc Clin Oncol – volume: 112 start-page: 46 year: 2020 end-page: 54 ident: bib24 article-title: HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade publication-title: J Natl Cancer Inst – volume: 17 start-page: 320 year: 2021 end-page: 330 ident: bib1 article-title: Management of early-stage human epidermal growth factor receptor 2-positive breast cancer publication-title: JCO Oncol Pract – volume: 148 start-page: 2614 year: 2021 end-page: 2627 ident: bib15 article-title: Early response by MR imaging and ultrasound as predictor of pathologic complete response to 12-week neoadjuvant therapy for different early breast cancer subtypes: combined analysis from the WSG ADAPT subtrials publication-title: Int J Cancer – volume: 7 start-page: 978 year: 2021 end-page: 984 ident: bib20 article-title: Three-year follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual ERBB2 blockade in patients with ERBB2-positive breast cancer: a secondary analysis of the TRAIN-2 randomized, phase 3 trial publication-title: JAMA Oncol – volume: 13 start-page: 25 year: 2012 end-page: 32 ident: bib5 article-title: Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial publication-title: Lancet Oncol – volume: 23 start-page: 36 year: 2021 ident: bib16 article-title: Magnetic resonance imaging and ultrasound for prediction of residual tumor size in early breast cancer within the ADAPT subtrials publication-title: Breast Cancer Res – volume: 2 start-page: 751 year: 2016 end-page: 760 ident: bib4 article-title: Association of pathologic complete response to neoadjuvant therapy in HER2-positive breast cancer with long-term outcomes: a meta-analysis publication-title: JAMA Oncol – volume: 48 start-page: 3342 year: 2012 end-page: 3354 ident: bib3 article-title: Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy publication-title: Eur J Cancer – volume: 22 start-page: 858 year: 2021 end-page: 871 ident: bib10 article-title: Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial publication-title: Lancet Oncol – volume: 30 start-page: 921 year: 2019 end-page: 926 ident: bib23 article-title: De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study publication-title: Ann Oncol – volume: 37 start-page: 2226 year: 2019 end-page: 2234 ident: bib18 article-title: NAB-paclitaxel improves disease-free survival in early breast cancer: GBG 69–Geparsepto publication-title: J Clin Oncol – volume: 146 start-page: 262 year: 2020 end-page: 271 ident: bib12 article-title: Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple-negative early breast cancer: primary translational analysis of the WSG-ADAPT-TN trial publication-title: Int J Cancer – volume: 38 start-page: 4184 year: 2020 end-page: 4193 ident: bib19 article-title: Survival, pathologic response, and genomics in CALGB 40601 (Alliance), a neoadjuvant phase III trial of paclitaxel–trastuzumab with or without lapatinib in HER2-positive breast cancer publication-title: J Clin Oncol – volume: 31 start-page: 3997 year: 2013 end-page: 4013 ident: bib13 article-title: Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update publication-title: J Clin Oncol – volume: 26 start-page: 873 year: 2015 end-page: 879 ident: bib14 article-title: Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials) publication-title: Ann Oncol – volume: 28 start-page: 2768 year: 2017 ident: 10.1016/S1470-2045(22)00159-0_bib9 publication-title: Ann Oncol doi: 10.1093/annonc/mdx494 – volume: 13 start-page: 25 year: 2012 ident: 10.1016/S1470-2045(22)00159-0_bib5 article-title: Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(11)70336-9 – volume: 31 start-page: 1726 year: 2013 ident: 10.1016/S1470-2045(22)00159-0_bib7 article-title: Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2–overexpressing breast cancer: TBCRC 006 publication-title: J Clin Oncol doi: 10.1200/JCO.2012.44.8027 – volume: 11 start-page: 2474 year: 2021 ident: 10.1016/S1470-2045(22)00159-0_bib22 article-title: Impact of HER2 heterogeneity on treatment response of early-stage HER2-positive breast cancer: phase ii neoadjuvant clinical trial of t-DM1 combined with pertuzumab publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-20-1557 – volume: 29 start-page: 170 year: 2018 ident: 10.1016/S1470-2045(22)00159-0_bib11 article-title: A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade publication-title: Ann Oncol doi: 10.1093/annonc/mdx647 – volume: 26 start-page: 873 year: 2015 ident: 10.1016/S1470-2045(22)00159-0_bib14 article-title: Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials) publication-title: Ann Oncol doi: 10.1093/annonc/mdv106 – volume: 80 year: 2020 ident: 10.1016/S1470-2045(22)00159-0_bib17 article-title: Predictive value of HER2 expression, early response and tumor infiltrating lymphocytes (TILs) on efficacy of de-escalated pertuzumab+trastuzumab in the neoadjuvant WSG-ADAPT-HER2+/HR– trial publication-title: Cancer Res doi: 10.1158/1538-7445.SABCS19-P4-10-05 – volume: 38 start-page: 515 year: 2020 ident: 10.1016/S1470-2045(22)00159-0_bib21 article-title: De-escalated chemotherapy versus endocrine therapy plus pertuzumab+ trastuzumab for HR+/HER2+ early breast cancer (BC): first efficacy results from the neoadjuvant WSG-TP-II study publication-title: Proc Am Soc Clin Oncol doi: 10.1200/JCO.2020.38.15_suppl.515 – volume: 384 start-page: 164 year: 2014 ident: 10.1016/S1470-2045(22)00159-0_bib2 article-title: Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis publication-title: Lancet doi: 10.1016/S0140-6736(13)62422-8 – volume: 112 start-page: 46 year: 2020 ident: 10.1016/S1470-2045(22)00159-0_bib24 article-title: HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djz042 – volume: 30 start-page: 921 year: 2019 ident: 10.1016/S1470-2045(22)00159-0_bib23 article-title: De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study publication-title: Ann Oncol doi: 10.1093/annonc/mdz055 – volume: 2 start-page: 751 year: 2016 ident: 10.1016/S1470-2045(22)00159-0_bib4 article-title: Association of pathologic complete response to neoadjuvant therapy in HER2-positive breast cancer with long-term outcomes: a meta-analysis publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2015.6113 – volume: 18 start-page: 545 year: 2017 ident: 10.1016/S1470-2045(22)00159-0_bib6 article-title: HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(17)30021-9 – volume: 31 start-page: 3997 year: 2013 ident: 10.1016/S1470-2045(22)00159-0_bib13 article-title: Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update publication-title: J Clin Oncol doi: 10.1200/JCO.2013.50.9984 – volume: 148 start-page: 2614 year: 2021 ident: 10.1016/S1470-2045(22)00159-0_bib15 article-title: Early response by MR imaging and ultrasound as predictor of pathologic complete response to 12-week neoadjuvant therapy for different early breast cancer subtypes: combined analysis from the WSG ADAPT subtrials publication-title: Int J Cancer doi: 10.1002/ijc.33495 – volume: 17 start-page: 320 year: 2021 ident: 10.1016/S1470-2045(22)00159-0_bib1 article-title: Management of early-stage human epidermal growth factor receptor 2-positive breast cancer publication-title: JCO Oncol Pract doi: 10.1200/OP.21.00020 – volume: 7 start-page: 978 year: 2021 ident: 10.1016/S1470-2045(22)00159-0_bib20 article-title: Three-year follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual ERBB2 blockade in patients with ERBB2-positive breast cancer: a secondary analysis of the TRAIN-2 randomized, phase 3 trial publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2021.1371 – volume: 22 start-page: 858 year: 2021 ident: 10.1016/S1470-2045(22)00159-0_bib10 article-title: Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(21)00122-4 – volume: 38 start-page: 4184 year: 2020 ident: 10.1016/S1470-2045(22)00159-0_bib19 article-title: Survival, pathologic response, and genomics in CALGB 40601 (Alliance), a neoadjuvant phase III trial of paclitaxel–trastuzumab with or without lapatinib in HER2-positive breast cancer publication-title: J Clin Oncol doi: 10.1200/JCO.20.01276 – volume: 48 start-page: 3342 year: 2012 ident: 10.1016/S1470-2045(22)00159-0_bib3 article-title: Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy publication-title: Eur J Cancer doi: 10.1016/j.ejca.2012.05.023 – volume: 146 start-page: 262 year: 2020 ident: 10.1016/S1470-2045(22)00159-0_bib12 article-title: Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple-negative early breast cancer: primary translational analysis of the WSG-ADAPT-TN trial publication-title: Int J Cancer doi: 10.1002/ijc.32488 – volume: 23 start-page: 36 year: 2021 ident: 10.1016/S1470-2045(22)00159-0_bib16 article-title: Magnetic resonance imaging and ultrasound for prediction of residual tumor size in early breast cancer within the ADAPT subtrials publication-title: Breast Cancer Res doi: 10.1186/s13058-021-01413-y – volume: 81 year: 2021 ident: 10.1016/S1470-2045(22)00159-0_bib25 article-title: The DAPHNE trial: a feasibility study of chemotherapy de-escalation based on response to neoadjuvant paclitaxel-HP (THP) in HER2-positive breast cancer publication-title: Cancer Res doi: 10.1158/1538-7445.SABCS20-PD3-05 – volume: 37 start-page: 2226 year: 2019 ident: 10.1016/S1470-2045(22)00159-0_bib18 article-title: NAB-paclitaxel improves disease-free survival in early breast cancer: GBG 69–Geparsepto publication-title: J Clin Oncol doi: 10.1200/JCO.18.01842 – volume: 26 start-page: 821 year: 2020 ident: 10.1016/S1470-2045(22)00159-0_bib8 article-title: TBCRC023: a randomized phase II neoadjuvant trial of lapatinib plus trastuzumab without chemotherapy for 12 versus 24 weeks in patients with HER2-positive breast cancer publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-19-0851 |
| SSID | ssj0017105 |
| Score | 2.5791101 |
| Snippet | Several de-escalation neoadjuvant strategies have been investigated to reduce the use of chemotherapy in HER2-positive early breast cancer using pathological... SummaryBackgroundSeveral de-escalation neoadjuvant strategies have been investigated to reduce the use of chemotherapy in HER2-positive early breast cancer... Summary Background Several de-escalation neoadjuvant strategies have been investigated to reduce the use of chemotherapy in HER2-positive early breast cancer... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 625 |
| SubjectTerms | Antibodies, Monoclonal, Humanized Antineoplastic Combined Chemotherapy Protocols - adverse effects Biopsy Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - pathology Cancer therapies Chemotherapy Clinical trials Drug therapy ErbB-2 protein Female Gene expression Hematology, Oncology, and Palliative Medicine Hormones - therapeutic use Humans Immunotherapy Inflammation Invasiveness Lymph nodes Medical prognosis Monoclonal antibodies Neoadjuvant Therapy Neoplasm Recurrence, Local - pathology Neoplasm Staging Paclitaxel Patients Surgery Targeted cancer therapy Translation Trastuzumab Tumors |
| Title | De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR–): survival outcomes from a multicentre, open-label, randomised, phase 2 trial |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S1470204522001590 https://www.clinicalkey.es/playcontent/1-s2.0-S1470204522001590 https://dx.doi.org/10.1016/S1470-2045(22)00159-0 https://www.ncbi.nlm.nih.gov/pubmed/35405088 https://www.proquest.com/docview/2656126541 https://www.proquest.com/docview/2649592251 |
| Volume | 23 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9NAEF4glRAXxJtAqQaJQyuyxF47fnBBoU2JkFpVaStys_wYU1CwTWzzOvEf-If8EmbWj14o5ZJI9o5X9n47-83uPIR4FnoqTGPTkp6DStquimRkObyR78a2zQm9I45GPjh05qf22-Vk2W64la1bZacTtaJO8pj3yMfK4TqOXLX6VfFZctUoPl1tS2hcExsmMREu3eAue4PLdBsXRtN2Dclp188jeMbH_cVtpXaYOfjSuGhtuoh76jVo_5a42ZJHmDajfVtcxeyOuH7QHo_fvTLYQ4klfXUikAlkmIfJx5qocgUFrqv6R_0pjKBY1SVU67DsLjQhWN-Bt2QhX-v_vK7gq062D2RUcyLvb7iCDxnMZwslG0-vLziCM6K8eYZAehMLMt9lhu_D5hZy6mSI2Om9gpjBtYbtd8dv5HRvenQi-UHPx_PF75-_dl5CWZPKItADdUzjgSVw3AuEoB0etQcpPZJLfUmCLa5GQGtskhNIMRlBcUZrMSjQJUjuidP92cnuXLZlHmQ8MVQlffRCNwntiasmqevGsZNERhIrZcSeb3NdDj8y0eHiWR7b06FNjS0HLZewlKRo3ReDjF71oYDETq2JzyQlNmh8LZ_oEToEupSs0hTVUNjdAAdxmwOdS3Gsgt7ZjXERMC4CpQKNi8AYihe9WNEkAblMwOnQE3QRrqSTA1qmLhN0_yaIZatZysAMSmrdSCudD1-LkqTXS7bkqSFF_9PpZgfwoO_nfL4NxdP-Ng0rHyiFhOCa25B57dOKQG0eNBOj_z68n8jk_9G_H_5Y3FAcUKJdSDfFoFrX-IRoXhVt6blMv96uuSU2Xs8OjxZ_ACUuTWM |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Zb9NAEF5KkIAXxE2gwCCB1IoscdaODySEItKS0kOoTUXeFh9rCgq28UEpT_wH_gc_il_CzDp2XyjlpU-R7J3dJPPNzszuHIw99l3hx-HA5K6tBLccEfDAtOkg3wktiwp6B5SNvL1jT_atN7PhbIn9anJhKKyy2RP1Rh2lIZ2R94VNfRypa_XL7AunrlF0u9q00KhhsamODtFlK15sjJG_T4RYX5u-mvBFVwEeDg1Rck-5vhP51tARw9hxwtCOAiMKhTBC17OoDYQXDJRNvZpcct98CwebtjId_OpRrEyc9zy7YNEVI8qPM2sdvIFTh0wOLMfgVOb9OGOov9c-XBFilSwVjxsn6cKTbF2t89avsisLYxVGNbqusSWVXGcXtxfX8TfOdcaKqwK5jAZrBIlK_ehThaZ5CZnKy-p79dkPIJtXBZS5XzQP6pSvI6AjYEhz_ZlWJRzq4v6ATjwVDv-m5vAxgcnaruB1ZNlX1YMDNLHTRAHu0yor05wn6oNfv1JUqhkCCrIvISQw57Dybu81H41Hb6ecJnran-z-_vFz9TkUFW6RKGSACyP_VQGUZwM-6ABLHbGKU1JrMY5iouY9QJ0epSgUKupBdoC6HwTolic32f6ZAOAW6yT4U-8wiKzYHHpkFIUG8tf00BxTNoI8Ri84VqLLrIbBMlzUXKfWH3PZBtcRLiThQgohNS6k0WXPWrKsLjpyGoHdoEc2GbWoAySqxdMInb8RqmKxkxVyIAscXVMLXX9fkyKl21IujLXaCPufRZcbgMt2nWP57rJH7WtkK11g-YjgisagO--hBsIxt2vBaP8fOr8kZ-Puvyd_yC5NpttbcmtjZ_MeuywomUWHry6zTplX6j6amGXwQMs1sPdnvZH8ARfWhqU |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Zb9NAEF5KKlW8IM4SKDBIILUiS5y14wOpQoEkpJRGVdqKvpm1vaagYAcflPLEf-Bf8TP4Jcz46gulvPQpkr2zK2fn-GZ3DsYeS1vI0O_p3DaV4IYlPO7pJh3kW75hUEFvj7KRd6bm5MB4c9g_XGK_6lwYCqusdWKhqIPYpzPyrjCpjyN1re6GVVjE7nD8YvGFUwcpummt22nIqs1CsFmUG6uSPLbVyTG6c-nm1hD3_okQ49H-qwmvOg5wv6-JjDvKllYgjb4l-qFl-b4ZeFrgC6H5tmNQiwjH6ymT-jjZ5NpJAwfrptIt_KwgVDrOe5ktW2j10RFcfjma7s6aOw2rDKjsGZbGqQj8aT5Rd695uC7EBuEYh2tnWcqzkHBhEcfX2NUKysKg5L3rbElFN9jKTnVZf_NSa6i4SpEHEM4GEKlYBp9yBO4ZLFSS5d_zz9KDxTxPIUtkWj8oE8JOgA6IIU6K3zjP4Lgo_Q_o4lNZ8W9qDh8jmIxmgpdxZ19VB44QgMeRAtTiapHFCY_UB1m-UlTIGTwKwc_AJ1ZPYP3d3ms-GA529zlN9LQ7mf3-8XPjOaQ5KlAUQcCFkTtUCpSFAxKK8MsinhWnpMZjHIVIzTuAFj-IUWRU0IHFESIDEFA0RLnFDi6EBW6zVoSfeodBYIR63yHI5Gu4v7qDYE2ZKAIh-sihEm1m1Bvs-lVFdmoMMneb0DviC5f4whXCLfjC1drsWUO2KEuSnEdg1tzj1vm2aCFcNJrnEVp_I1RppedSt-emOLqkFkV1_oIUKe2GsoJyJUT7n0XXagZ3m3VOpb_NHjWvcVvpeksiB-c0Bp19B-0TjlktBaP5f-h0k1yRu_-e_CFbQaXivt2abt9jVwRluhSxrWuslSW5uo_4M_MeVIIN7P1F65I_AgKRgA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=De-escalated+neoadjuvant+pertuzumab+plus+trastuzumab+therapy+with+or+without+weekly+paclitaxel+in+HER2-positive%2C+hormone+receptor-negative%2C+early+breast+cancer+%28WSG-ADAPT-HER2%2B%2FHR%E2%80%93%29%3A+survival+outcomes+from+a+multicentre%2C+open-label%2C+randomised%2C+phase+2+trial&rft.jtitle=The+lancet+oncology&rft.au=Nitz%2C+Ulrike&rft.au=Gluz%2C+Oleg&rft.au=Graeser%2C+Monika&rft.au=Christgen%2C+Matthias&rft.date=2022-05-01&rft.pub=Elsevier+Ltd&rft.issn=1470-2045&rft.eissn=1474-5488&rft.volume=23&rft.issue=5&rft.spage=625&rft.epage=635&rft_id=info:doi/10.1016%2FS1470-2045%2822%2900159-0&rft.externalDocID=S1470204522001590 |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F14702045%2FS1470204522X00053%2Fcov150h.gif |